WO2006063329A3 - Enhanced protection against mycobacterium tuberculosis - Google Patents

Enhanced protection against mycobacterium tuberculosis Download PDF

Info

Publication number
WO2006063329A3
WO2006063329A3 PCT/US2005/044871 US2005044871W WO2006063329A3 WO 2006063329 A3 WO2006063329 A3 WO 2006063329A3 US 2005044871 W US2005044871 W US 2005044871W WO 2006063329 A3 WO2006063329 A3 WO 2006063329A3
Authority
WO
WIPO (PCT)
Prior art keywords
protection against
mycobacterium tuberculosis
enhanced protection
against mycobacterium
present
Prior art date
Application number
PCT/US2005/044871
Other languages
French (fr)
Other versions
WO2006063329A2 (en
Inventor
Jeffrey K Actor
Marian L Kruzel
Original Assignee
Univ Texas
Jeffrey K Actor
Marian L Kruzel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Jeffrey K Actor, Marian L Kruzel filed Critical Univ Texas
Publication of WO2006063329A2 publication Critical patent/WO2006063329A2/en
Publication of WO2006063329A3 publication Critical patent/WO2006063329A3/en
Priority to US11/810,477 priority Critical patent/US20070259007A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Abstract

The method of the present invention provides a novel use of Lactoferrin as an adjuvant composition suitable to be used in vaccines. More specifically, the present invention is directed to the use of Lactoferrin to augment a vaccine efficacy by generation of T helper response and subsequent protection against challenge with a virulent pathogen. Also provided by the present invention is a method of manufacture of the adjuvant and it use as medicament.
PCT/US2005/044871 1999-10-19 2005-12-09 Enhanced protection against mycobacterium tuberculosis WO2006063329A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/810,477 US20070259007A1 (en) 1999-10-19 2007-06-06 Lactoferrin: an adjuvant for vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63541404P 2004-12-10 2004-12-10
US60/635,414 2004-12-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/810,477 Continuation-In-Part US20070259007A1 (en) 1999-10-19 2007-06-06 Lactoferrin: an adjuvant for vaccines

Publications (2)

Publication Number Publication Date
WO2006063329A2 WO2006063329A2 (en) 2006-06-15
WO2006063329A3 true WO2006063329A3 (en) 2007-01-04

Family

ID=36578658

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/044871 WO2006063329A2 (en) 1999-10-19 2005-12-09 Enhanced protection against mycobacterium tuberculosis

Country Status (1)

Country Link
WO (1) WO2006063329A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277817B1 (en) * 1990-03-08 2001-08-21 Ferro Dynamics Inc. Human lactoferrin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277817B1 (en) * 1990-03-08 2001-08-21 Ferro Dynamics Inc. Human lactoferrin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZIMECKI M. ET AL.: "Systemic or local co-administration of lactoferrin with sensitizing dose of antigen enhances delayed type hypersensitivity in mice", IMMUNOLOGY LETTERS, vol. 74, 2000, pages 183 - 188, XP003005416 *

Also Published As

Publication number Publication date
WO2006063329A2 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
WO2005002621A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
WO2007024941A3 (en) Polyvalent vaccine
EP2712625A3 (en) Vaccines comprising TB 10.4
WO2006071989A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
WO2007092792A3 (en) Yeast-based vaccine for inducing an immune response
WO2005087238A3 (en) Method for stimulating the immune, inflammatory or neuroprotective response
WO2009072767A3 (en) A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant
WO2006032475A3 (en) Staphylococcal immunogenic compositions
WO2007104451A8 (en) Live attenuated bordetella strains as a single dose vaccine against whooping cough
WO2009089535A3 (en) Polypeptide vaccine and vaccination strategy against mycobacterium
WO2010019262A3 (en) Polyvalent vaccine
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2006120439A3 (en) Cellular vaccine and use thereof
WO2010012069A8 (en) Multivalent vaccines based on papaya mosaic virus and uses thereof
WO2008128065A3 (en) Tuberculosis vaccine and method of using same
WO2006136460A3 (en) New adjuvant
WO2008056174A3 (en) Novel compositions and uses thereof
WO2010034974A3 (en) Tuberculosis vaccines targeted to cd40
WO2003059385A3 (en) Hiv vaccine and method of use
WO2010053610A3 (en) Stable anthrax vaccine formulations
AU2007272785A8 (en) Methods to elicit, enhance and sustain immune responses against MHC class-I restricted epitopes, for prophylactic or therapeutic purposes
WO2005058349A3 (en) Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases
WO2006064378A3 (en) Adjuvant activity of gastrointestinal peptides
GB2444676A (en) Adjuvanted vaccine
WO2006024240A3 (en) Vaccine composition against hepatitis c virus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11810477

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 11810477

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 05853720

Country of ref document: EP

Kind code of ref document: A2